Titanium Dioxide
Active ingredient
Sold as Jack Black · Max Mineral · EltaMD UV Restore · Huey Daily Mineral · CLE CCC Warm Light
- Drug class
- -
- Availability
- Over-the-counter
- Routes
- Topical
- Markets covered
- 3
- Products on record
- 88
- FDA reports (12 mo)
- 19
Overview
Plain-language summary, compiled from the cited regulatory records
Titanium Dioxide is an active ingredient used in sun protection products [1]. It is approved for use to help prevent sunburn when used as directed with other sun protection measures [1]. Additionally, it is indicated to decrease the risk of skin cancer and early skin aging caused by the sun [1].
This ingredient is available under various brand names, including Kids Mineral Sunscreen SPF50 and DR.JART EVERY SUN DAY MINERAL SUN SCREEN [1]. In the past 12 months, there have been 19 adverse event reports associated with products containing Titanium Dioxide [2]. The top reported reactions include hypersensitivity, abdominal pain upper, madarosis, burns third degree, and death [2].
This is not medical advice. Consult a qualified healthcare professional.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| US United States | FDA | 81 | May 21, 2026 |
| CA Canada | Health Canada | 6 | May 7, 2026 |
| GB United Kingdom | MHRA | 1 | August 22, 2025 |
USUnited States· FDA
81 products
Uses
Uses helps prevent sunburn if used as directed with other sun protection measures (see Directions ), decreases the risk of skin cancer and early skin aging caused by the sun
How to take
CACanada· Health Canada
6 products
6 products on record with this regulator. Detailed label text (uses, dosage, side effects) is being ingested — the original document is linked under Sources [2].
GBUnited Kingdom· MHRA
1 product
1 product on record with this regulator. Detailed label text (uses, dosage, side effects) is being ingested — the original document is linked under Sources [3].
Sources & citations
- [1]FDA DailyMed · 003123d2-9675-fd… · revised July 28, 2025 [PDF]
- [2]Health Canada (DPD) · 02406926 · revised March 22, 2025
- [3]MHRA (UK) · PL002400366 · revised August 22, 2025
- [4]OpenFDA adverse-event reports (US), 12 months ending June 4, 2026.
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.